The HemOnc Pulse
The HemOnc Pulse
Advertisement
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | May 30, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 10, 2024
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 8, 2024
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 28, 2024
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Advertisement
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 15, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | February 14, 2024
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | January 4, 2024
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
Jerald Radich, MDAcute Myeloid Leukemia | January 17, 2024
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | December 14, 2023
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 19, 2023
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 16, 2023
We saw patients [who] were going to die, and it saved their life and then it's gone and it's shocking," she explained.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 2, 2023
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | October 19, 2023
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Advertisement
Advertisement
Editorial Board